Skip to main content

Kilitch Drugs (India) Ltd

Stage 2 · Advancing · week 2Setup 8.7 ★★★ PrimeStrong +13.2

Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. More about the company

₹256.3
-1.71% today
₹896 Cr · Small cap
Market Neutral — FadingHealth Care 45.7% in Stage 2-1.4 pts / 20dPharmaceuticals 53.8%+3.8 pts
Loading price chart…
vs 52W High
-1.7%
₹124.5 lo₹260.7 hi
Near 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 2
1w13w26w
Week 2 — fresh breakout, verify structure
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
48.1%
200 DMA: ₹173.1 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
3.77x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑ ⇈
Accelerating · MA20 +14.6% vs MA50 +5.6% / 10d
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+41.6%
3M
+39.9%
6M
+91.4%
YTD
+46.6%
1Y
+51.6%
Sector
Health Care
↓ Peaking
Stage 2%
45.7%
20d Δ
-1.4pp
1M return
-1.8%
3M return
+4.4%
Sector Stage-2 % · last 20 days
This stock ranks #21 of 77 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
↑ Building
Stage 2%
53.8%
20d Δ
+3.8pp
1M return
-0.9%
3M return
+3.6%
Industry Stage-2 % · last 20 days
Ranks #18 of 61 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-07-12 → 2026-10-07
S2 28w
S2 16w
S4 31w
2023-07-122026-10-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 2w → S3 7w → S2 28w → S3 13w → S4 4w → S1 11w → S4 12w → S1 8w → S4 5w → S1 3w → S2 16w → S3 8w → S4 31w → S1 5w → S2 9w → S3 4w → S2 2w current
Total tracked: 168 weeks across 17 stage runs.
Scan Membership
Prop Scan
Latest: 2026-10-05
Breakout Watch
Latest: 2026-09-25
Pullback Hunter
Latest: 2026-08-13
31 appearances in last 60 days. First seen: 2025-04-30.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-07S2
Wk 2 · Vol 3.77x
2026-10-06S2
Wk 2 · Vol 18.78x
2026-10-05S2
Wk 2 · Vol 8.07x
2026-10-01S2
Wk 1 · Vol 0.76x
2026-09-30S2
Wk 1 · Vol 1.13x
2026-09-29S2
Wk 1 · Vol 0.50x
2026-09-28S2
Wk 1 · Vol 1.05x
2026-09-25S23→2
Wk 1 · Vol 1.11x
2026-09-24S3
Wk 4 · Vol 3.03x
2026-09-23S3
Wk 4 · Vol 0.98x
2026-09-22S3
Wk 4 · Vol 0.90x
2026-09-21S3
Wk 3 · Vol 1.63x
Sector Peers — Stage 2All →
KOPRAN
wk 19 · -5.0% from hi
9.0
SMSPHARMA
wk 3 · -3.0% from hi
8.7
BAFNAPH
wk 17 · 0.0% from hi
8.6
ZIMLAB
wk 21 · 0.0% from hi
8.3
SHILPAMED
wk 22 · -0.2% from hi
8.0
Moving averages & range
50 DMA
₹191.6
200 DMA
₹173.1
52W High
₹260.7
52W Low
₹124.5
5D Low
₹213.3
Resistance levels (recent highs)
20d High
₹260.7
60d High
₹260.7
120d High
₹260.7
250d High
₹260.7
Next resistance
+1.7%
to 20d High
P/E (TTM)
20.5
Forward 11.9
Earnings Growth (YoY)
+26.5%
Revenue +46.3%
ROE
+12.4%
Profit margin +12.8%
About this companyHealth Care· Pharmaceuticals

Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anticoagulant, narcotic, oncology, ophthalmic, antifungal, corticosteroid, anticoagulant, and other applications, as well as vaccines, veterinary products, iron supplements for anemia, Klavmox, and Onecef. It also provides oral formulations, including tablets, capsules, dry syrup, and oral powder for antibiotic, anti-diabetic, cardiovascular, and other areas; effervescent tablets and powders, such as Roipar, Duregra, and Roivit; and nutritional products, including Celtine. In addition, the company offers cosmetics, which include oil, lotion, liquid to cream, paste in skin, and personal and hair care products; herbal products for use in sore throat and prostate problems, as well as a supplement for diabetes, obesity, libido, and other conditions; ortho rehabilitation and implants; and medical devices comprising C-Seal, a skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Further, it provides PH-7 which reduces acid content of the stomach; SRO kit for treating childhood diarrhea; 9-VIT for use in surgery, extensive burns, fractures, and other trauma; and HPURE for sore throat and cough. The company exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.